TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12426500

Group type: EXPERIMENTAL
Intervention: Direct composite restorations
Number of subjects: 117

Group type: COMPARATOR
Intervention: Full-coverage metal-ceramic crowns
Number of subjects: 117
Study: 10578189

Group type: EXPERIMENTAL
Intervention: Panoramic Radiography (PR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Panoramic Radiography combined with Intraoral Radiography (PR+IR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 37
Study: 8952648

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1748814

Group type: EXPERIMENTAL
Intervention: 25% MPD
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 50% MPD
Number of subjects: 25

Group type: COMPARATOR
Intervention: Skin type
Number of subjects: 25
Study: 6291138

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31101617

Group type: EXPERIMENTAL
Intervention: High viral load of species group alpha-9 non-HPV16 oncogenic types
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Change of viral load from low to high levels
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: High DNA load of species group alpha-9 non-HPV16 oncogenic types
Number of subjects: 439
Study: 28679502

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg every 4 hours)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Slower finishers
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Greater weight loss
Number of subjects: 89
Study: 26691817

Group type: EXPERIMENTAL
Intervention: Home-based exercise (n = 47)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (n = 48)
Number of subjects: 95
Study: 22459616

Group type: EXPERIMENTAL
Intervention: 0.1 mg LGD-4033
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 0.3 mg LGD-4033
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 1.0 mg LGD-4033
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 20842429

Group type: EXPERIMENTAL
Intervention: Exercise training for 12 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard care (CT)
Number of subjects: 20
Study: 19703065

Group type: EXPERIMENTAL
Intervention: Swimming intervention for 6 weeks
Number of subjects: 30
Study: 17707751

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg before the intervention, and 200 mg twice daily for 6 months after the procedure)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (standard care with aspirin and clopidogrel)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 274
Study: 15204051

Group type: EXPERIMENTAL
Intervention: Alcohol condition
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 10
Study: 11524058

Group type: EXPERIMENTAL
Intervention: rosuvastatin 1 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: rosuvastatin 2.5 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: rosuvastatin 80 mg
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: rosuvastatin (all doses)
Number of subjects: 206

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 206
Study: 9284718

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg qd p.o. for four consecutive days starting two days before immunization)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 71
Study: 8313933

Group type: EXPERIMENTAL
Intervention: Deflazacort 30 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Deflazacort 60 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3791867

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physiological saline infusion
Number of subjects: 10
Study: 31874290

Group type: EXPERIMENTAL
Intervention: Restarting anticoagulation for stroke prevention in atrial fibrillation after cSDH evacuation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Timing of anticoagulation reinitiation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Perceived risk of stroke and SDH reaccumulation
Number of subjects: 81
Study: 30230681

Group type: EXPERIMENTAL
Intervention: Autogenous DDM granules
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bio-Oss granules
Number of subjects: 40
Study: 27447483

Group type: EXPERIMENTAL
Intervention: Very early stepping verticalization protocol (15 sessions of 30 minutes each using a tilt table with robotic stepping device)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional physiotherapy alone
Number of subjects: 40
Study: 24722495

Group type: EXPERIMENTAL
Intervention: Peer Leader (PL) intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Both groups (PL and CHW)
Number of subjects: 116
Study: 22878279

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Medical arm
Number of subjects: 1077
Study: 20978144

Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg
Number of subjects: 60
Study: 18855269

Group type: EXPERIMENTAL
Intervention: 40 mg/day telmisartan
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 mg/day telmisartan
Number of subjects: 30
Study: 16026559

Group type: EXPERIMENTAL
Intervention: Cerebellar stimulation ON
Number of subjects: 5
Study: 12453548

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 12135033

Group type: EXPERIMENTAL
Intervention: Tapering course of vancomycin
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Pulsed dosing of vancomycin
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: High-dose vancomycin (> or =2 g/day)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Low-dose metronidazole (< or =1 g/day)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 163
Study: 9834039

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study: 8122510

Group type: EXPERIMENTAL
Intervention: Active immunization with third party leukocytes
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 2679473

Group type: EXPERIMENTAL
Intervention: Hourly doses of clonidine hydrochloride followed by maintenance therapy (group 1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: An initial dose of clonidine followed by hourly placebo and subsequent maintenance therapy (group 2)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Maintenance therapy without prior loading (group 3)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All groups (1, 2, and 3)
Number of subjects: 64
Study: 766165

Group type: EXPERIMENTAL
Intervention: Tyloxapol (Tacholiquin, Alevaire)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tyloxapol
Number of subjects: 24
Study: 30924997

Group type: EXPERIMENTAL
Intervention: 3D deep convolutional neural network (CNN) for breast cancer diagnosis
Number of subjects: 1537
Study: 28642008

Group type: EXPERIMENTAL
Intervention: Once-daily concurrent chemoradiotherapy (66 Gy in 33 fractions of 2 Gy over 45 days)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Twice-daily concurrent chemoradiotherapy (45 Gy in 30 fractions of 1.5 Gy over 19 days)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Twice-daily concurrent chemoradiotherapy
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Once-daily concurrent chemoradiotherapy
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 547
Study: 25934525

Group type: EXPERIMENTAL
Intervention: Sitagliptin (25 mg titrated up to 50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glimepiride (0.5 mg titrated up to 1 mg)
Number of subjects: 20
Study: 24204757

Group type: EXPERIMENTAL
Intervention: r/LPV + RAL
Number of subjects: 210

Group type: COMPARATOR
Intervention: r/LPV + N(t)RTI
Number of subjects: 210
Study: 21742276

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 6

Group type: COMPARATOR
Intervention: Rest (Control)
Number of subjects: 6
Study: 19403270

Group type: EXPERIMENTAL
Intervention: Social recovery orientated cognitive behavioural therapy (SRCBT)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Case management alone (CMA)
Number of subjects: 77
Study: 16368639

Group type: EXPERIMENTAL
Intervention: Attainable goal group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Unattainable goal group
Number of subjects: 24
Study: 15486607

Group type: EXPERIMENTAL
Intervention: Sertraline or Fluoxetine
Number of subjects: 19
Study: 11110112

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9058213

Group type: EXPERIMENTAL
Intervention: Intraoperative plasmapheresis (IP)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (no intraoperative plasmapheresis)
Number of subjects: 293
Study: 8371822

Group type: EXPERIMENTAL
Intervention: Ranitidine (2 dd 150 mg) for 2 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 30
Study: 31292181

Group type: EXPERIMENTAL
Intervention: Disease activity‐guided tapering of biological disease-modifying antirheumatic drugs (bDMARDs)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Continuation of bDMARDs as usual care
Number of subjects: 180
Study: 28267942

Group type: EXPERIMENTAL
Intervention: Room air cerebral tissue oxygen saturation
Number of subjects: 81
Study: 25399758

Group type: EXPERIMENTAL
Intervention: Yellow post-it notes with a handwritten message on follow-up questionnaires
Number of subjects: 499

Group type: COMPARATOR
Intervention: No yellow post-it notes on follow-up questionnaires (Control)
Number of subjects: 499
Study: 23886347

Group type: EXPERIMENTAL
Intervention: Exercise intervention (n = 33)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Diet intervention (n = 35)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 101
Study: 21713327

Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose, 10 mg daily maintenance dose)
Number of subjects: 201

Group type: COMPARATOR
Intervention: High-dose clopidogrel (600 mg loading dose, 150 mg daily maintenance dose)
Number of subjects: 201
Study: 19958415

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher dietary magnesium intake
Number of subjects: 0
Study: 17234041

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions with psychopharmacology as an adjunct
Number of subjects: 33

Group type: COMPARATOR
Intervention: Psychotropic medication with psychosocial methods as an occasional adjunct
Number of subjects: 33
Study: 14760258

Group type: EXPERIMENTAL
Intervention: Live quadrivalent rotavirus vaccine (QRV)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 11596949

Group type: EXPERIMENTAL
Intervention: CBF-targeted management strategy
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Epinephrine administration
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Dopamine administration (larger than median dose)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: History of drug abuse
Number of subjects: 189

Group type: COMPARATOR
Intervention: ICP-targeted management strategy
Number of subjects: 189
Study: 9573435

Group type: EXPERIMENTAL
Intervention: Age appropriate intervention (program taught in Grades 6, 7, and 8)
Number of subjects: 2483

Group type: EXPERIMENTAL
Intervention: Intensive intervention (program taught in Grade 7)
Number of subjects: 2483

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2483
Study: 8145931

Group type: EXPERIMENTAL
Intervention: Thiamine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3050087

Group type: EXPERIMENTAL
Intervention: Folinic acid 20 mg/week
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31567887

Group type: EXPERIMENTAL
Intervention: Split-dose PEG (4000 mL/1.73 m PEG solution, half the dose day before and half on the day of colonoscopy)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Single-dose PEG (4000 mL/1.73 m PEG solution day before colonoscopy)
Number of subjects: 220
Study: 29654502

Group type: EXPERIMENTAL
Intervention: 20% BSFLM
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 40% BSFLM
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 60% BSFLM
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 80% BSFLM
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 100% BSFLM
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (100% fishmeal)
Number of subjects: 240
Study: 27484356

Group type: EXPERIMENTAL
Intervention: Delivery based on ductus venosus (DV) Doppler pulsatility index (PI) with safety-net criteria of very low STV on cardiotocography (CTG) and/or recurrent FHR decelerations
Number of subjects: 149

Group type: COMPARATOR
Intervention: CTG monitoring only
Number of subjects: 149

Group type: COMPARATOR
Intervention: CTG monitoring
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: DV monitoring with safety-net criteria
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Low STV and/or recurrent FHR decelerations
Number of subjects: 149
Study: 26216729

Group type: EXPERIMENTAL
Intervention: Cytotoxic therapy plus concurrent and maintenance bevacizumab
Number of subjects: 1107

Group type: COMPARATOR
Intervention: Cytotoxic therapy plus placebo
Number of subjects: 1107
Study: 23040721

Group type: EXPERIMENTAL
Intervention: Alcoholics Anonymous attendance (specifically the 'Added AA' subgroup)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Potential AA subgroup (those who would have attended AA if exposed to TSF)
Number of subjects: 0
Study: 20961574

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Enuresis alarm
Number of subjects: 104

Group type: COMPARATOR
Intervention: Enuresis alarm (as second line treatment)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Desmopressin (as second line treatment)
Number of subjects: 104
Study: 18416257

Group type: EXPERIMENTAL
Intervention: CeeOn diffractive multifocal IOL (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Array refractive multifocal IOL (n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mix & match group (n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Phakic controls (not specified how many)
Number of subjects: 30
Study: 16894312

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (ascorbic acid 500 mg, D-alpha-tocopherol 945 IU, selenium 200 microg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 23
Study: 14680093

Group type: EXPERIMENTAL
Intervention: Face mask spirometry
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional mouthpiece
Number of subjects: 22
Study: 10962676

Group type: EXPERIMENTAL
Intervention: Contact endoscopy
Number of subjects: 8
Study: 8977677

Group type: EXPERIMENTAL
Intervention: Tacalcitol ointment (4 micrograms/g, once daily for 8 weeks)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 1456917

Group type: EXPERIMENTAL
Intervention: Forced-air warming (n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Warmed cotton blankets (n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (forced-air warming and warmed cotton blankets)
Number of subjects: 12
Study: 6530546

Group type: EXPERIMENTAL
Intervention: Dietary sodium reduced from approximately 110 to 45 mEq/24 h for a period of 24 days
Number of subjects: 124
Study: 31504099

Group type: EXPERIMENTAL
Intervention: 3'‐sialyllactose (3'SL) at 15 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 3'‐sialyllactosamine (3'SLN) at 15 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: lactodifucotetraose (LDFT) at 24 weeks
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Model including fasting glucose, prepregnancy BMI, gestational weight gain, age, parity, smoking, and history of macrosomia
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Model including fasting glucose, prepregnancy BMI, gestational weight gain, age, parity, smoking, history of macrosomia, and 3'SL
Number of subjects: 87
Study: 28917383

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks for weeks 0-12, then every 4 weeks during LTE
Number of subjects: 1346
Study: 26806217

Group type: EXPERIMENTAL
Intervention: Daclizumab high-yield process (DAC HYP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25134636

Group type: EXPERIMENTAL
Intervention: Health promotion intervention targeting physical activity and healthy eating over a 10-week period, repeated yearly for 20 years.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health promotion intervention targeting physical activity and healthy eating with an increase in health-related quality of life due to body mass index decrease.
Number of subjects: 0
Study: 22544817

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) exercise program
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control Group (CG) program
Number of subjects: 151
Study: 19084683

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 100
Study: 17942835

Group type: EXPERIMENTAL
Intervention: Regular stimulant use
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Increased affect regulation (decreased severity of depressive symptoms)
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Increased affect regulation
Number of subjects: 858
Study: 15801581

Group type: EXPERIMENTAL
Intervention: Smoking cessation aid
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Willingness to make another quit attempt
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Interest in reduction strategy
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Interest in nicotine replacement therapy (NRT)
Number of subjects: 391
Study: 11764874

Group type: EXPERIMENTAL
Intervention: TCP-coated AML femoral implant
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard AML femoral implant (control group)
Number of subjects: 92
Study: 8996038

Group type: EXPERIMENTAL
Intervention: Nutritional therapy (specific nutrients and supplements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food allergies (IgE-mediated reactions)
Number of subjects: 0
Study: 8504881

Group type: EXPERIMENTAL
Intervention: Diva supported intensified outpatient regimen (Diva group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intensified outpatient control (Control group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional outpatient control (Control group B)
Number of subjects: 56
Study: 3318089

Group type: EXPERIMENTAL
Intervention: Intravesical bacillus Calmette-Guerin (BCG)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Doxorubicin hydrochloride (Adriamycin [ADR])
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: BCG or ADR (in cases of treatment failure)
Number of subjects: 116
Study: 31836448

Group type: EXPERIMENTAL
Intervention: Roll (permitted to roll up sleeves)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No Roll (instructed to remain with long sleeves)
Number of subjects: 10
Study: 29514803

Group type: EXPERIMENTAL
Intervention: BI 695501
Number of subjects: 645

Group type: COMPARATOR
Intervention: Humira
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Switched from Humira to BI 695501
Number of subjects: 645
Study: 27726290

Group type: EXPERIMENTAL
Intervention: Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) regimen
Number of subjects: 851

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 851
Study: 24239451

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Various head positions
Number of subjects: 10
Study: 22418809

Group type: EXPERIMENTAL
Intervention: CCIV/TIV
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: CCIV/TIV with concomitant pneumococcal vaccine (PV)
Number of subjects: 2609

Group type: EXPERIMENTAL
Intervention: CCIV with PV
Number of subjects: 2609
Study: 20973324

Group type: EXPERIMENTAL
Intervention: Ice applied 5 minutes before injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ice applied 5 minutes after injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no ice application)
Number of subjects: 60
Study: 18273670

Group type: EXPERIMENTAL
Intervention: Ligasure
Number of subjects: 110

Group type: COMPARATOR
Intervention: Diathermy
Number of subjects: 110
Study: 16187176

Group type: EXPERIMENTAL
Intervention: Therapy (standard treatment for HCV)
Number of subjects: 10
Study: 12537187

Group type: COMPARATOR
Intervention: Standard prime (SP) volume (1,602 +/- 202 mL crystalloid prime, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP) (395 +/- 150 mL)
Number of subjects: 20
Study: 10768524

Group type: EXPERIMENTAL
Intervention: Behavioral training program consisting of gesture‐production exercises (35 sessions, 50 minutes each)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional treatment for aphasia
Number of subjects: 13
Study: 8822675

Group type: EXPERIMENTAL
Intervention: Balance System measures (leaning forward, leaning to the paretic side, maintaining symmetrical posture)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Functional Independence Measure (FIM)
Number of subjects: 20